{
    "clinical_study": {
        "@rank": "127908", 
        "arm_group": [
            {
                "arm_group_label": "DCVAC/PCa add on to Standard of Care", 
                "arm_group_type": "Experimental", 
                "description": "Combination therapy with DCVAC/PCa and Standard of Care"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Docetaxel as an Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DCVAC/PCa  added onto Standard of Care\n      therapy can improve survival times for patients with Metastatic Castration Resistant\n      Prostate Cancer"
        }, 
        "brief_title": "Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostate Cancer (PCa)", 
            "Prostate Cancer Metastatic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men aged \u2265 18 years\n\n          -  Histologically confirmed prostate cancer\n\n          -  Presence of skeletal metastasis (by CT or PET or MRI)\n\n          -  Disease progression documented by increasing PSA or two new lesions\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2\n\n        Exclusion Criteria:\n\n          -  Confirmed brain and/or leptomeningeal metastases\n\n          -  Prior chemotherapy for prostate cancer\n\n          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater\n\n          -  Other uncontrolled intercurrent illness\n\n          -  Treatment with immunotherapy against PCa\n\n          -  Clinically significant cardiovascular disease\n\n          -  Active autoimmune disease requiring treatment"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105675", 
            "org_study_id": "SP001", 
            "secondary_id": "2011-004735-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "DCVAC/PCa add on to Standard of Care", 
                "description": "DCVAC/PCa is the experimental therapy added on to Docetaxel", 
                "intervention_name": "DCVAC/PCa", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "DCVAC/PCa add on to Standard of Care", 
                    "Standard of Care"
                ], 
                "description": "Docetaxel is Standard of Care First Line Chemotherapy", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "taxotere"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunotherapy", 
            "Metastatic", 
            "Castrate Resistant", 
            "Prostate Cancer", 
            "Biological", 
            "Vaccine"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kralove", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jihlava", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liberec", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nova Ves pod Plesi", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 10", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 4", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 5", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha 8", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Usti nad Labem", 
                        "country": "Czech Republic"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zlin", 
                        "country": "Czech Republic"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Castrate-resistant Prostate Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival (all cause mortality)", 
            "safety_issue": "Yes", 
            "time_frame": "135 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Radiographic Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "135 weeks"
            }, 
            {
                "measure": "Duration to Prostate Specific Antigen (PSA) Progression", 
                "safety_issue": "No", 
                "time_frame": "135 weeks"
            }, 
            {
                "measure": "Changes in Quality of Life (QOL) assessed by European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30", 
                "safety_issue": "No", 
                "time_frame": "0, 10, 22, 37, 53, 65 weeks"
            }, 
            {
                "measure": "Changes in Pain assessed by EORTC QLQ-C30", 
                "safety_issue": "No", 
                "time_frame": "0, 10, 22, 37, 53, 65 weeks"
            }
        ], 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}